GeneDx Holdings Corp. (WGS) AI Stock Analysis

GeneDx Holdings Corp. operates as a health information company focused on disease diagnosis, treatment, and prevention through genomic and data-driven solutions. Its flagship platform, Centrellis, applies AI-driven health intelligence to assist biopharmaceutical companies across the drug discovery, clinical development, and commercialization process. The company also offers Sema4 Signal for precision oncology care and provides advanced sequencing and specialized genetic testing services. These testing capabilities include carrier screening, noninvasive prenatal testing, newborn screening, hereditary cancer testing, and COVID-19 testing solutions.

GeneDx increased revenue from $212.2M in FY2021 to $427.5M in FY2025, representing a 5-year revenue compound annual growth rate of 19.0%. Annual revenue grew 50.8% in FY2024 and 40.0% in FY2025. Gross margin expanded from -7.8% in FY2021 to 69.7% in FY2025, while operating margin narrowed from -210.3% to -2.8% over the same period. Annual net income improved from -$245.4M in FY2021 to -$21.0M in FY2025, with EPS rising to $1.40. Over the trailing twelve months, revenue reached $454.4M with an operating margin of -15.2% and EPS of -$3.63. For the latest quarter ended June 30, 2026, quarterly revenue grew 11.4% year-over-year.

As of June 30, 2026, GeneDx held $132.5M in cash and short-term investments against total debt of $167.4M, resulting in net debt of $34.9M. Total assets stood at $481.5M compared to shareholders' equity of $244.2M, with a current ratio of 3.30 and a debt-to-equity ratio of 0.69. Operating cash flow improved to $33.3M in FY2025 from -$28.5M in FY2024. Free cash flow was $14.3M in FY2025 after capital expenditures of $19.0M. Share count increased 306.0% over the five-year period.

At a share price of $63.61, GeneDx has a market capitalization of $1.90B and an enterprise value of $2.58B. The stock trades at a forward P/E of 63.3x, above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 4.2x compares to the peer median of 4.1x, while its EV-to-EBITDA ratio of 161.2x exceeds the peer median of 12.0x. Over the past year, the stock fell 46.3%, while the S&P 500 benchmark gained 16.8%. Over five years, the stock dropped 75.3% against an 83.0% gain for the S&P 500.

Wall Street coverage includes 7 Strong Buy ratings, 1 Buy rating, and no Hold or Sell recommendations. The mean price target is $93.50, which is 47.0% above the last closing price of $63.61. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $481.8M and EPS of $0.13. For the following fiscal year, seven analysts project revenue of $599.0M and EPS of $1.20. GeneDx beat EPS estimates in 3 of the last 4 quarters, and its next earnings date is October 27, 2026.

This page is an AI-written research summary of GeneDx Holdings Corp. (WGS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: WGS income statement, WGS balance sheet, WGS key metrics, WGS analyst forecast, WGS chart. See the WGS stock overview for the latest quote and news.